MCRB
Seres Therapeutics, Inc.
Key Financials
Operating Income
$-93971000
↑ 22.5%
Net Income
$5.7M
↑ 4088.2%
Revenue
$789000
↑ Infinity%
EPS (Diluted)
$0.64
↑ Infinity%
Total Liabilities
$94.0M
↓ 25.4%
Total Assets
$138.2M
↓ 1.2%
Shareholders' Equity
$44.2M
↑ 220.8%
Cash & Equivalents
$45.8M
↑ 48.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-3 | 8/13/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 8-K | 8/4/2026 | View on SEC |
| 424B5 | 8/4/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MCRB |
| Company Name | Seres Therapeutics, Inc. |
| CIK | 1609809 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617 945 9626 |